Radiotherapy na cututtukan huhu wanda ba za a iya cire su ta hanyar tiyata ba

Share Wannan Wallafa

Stereotactic jiki radiation far

Stereotactic body radiation far (SBRT), wanda kuma aka sani da stereotactic ablative radiotherapy (SABR). Tun lokacin da aka yi amfani da shi a cikin tsakiyar 1990s, SBRT ya bambanta kansa a cikin maganin cututtuka na mafi yawan ciwace-ciwacen daji saboda yawan ƙwayar ƙwayar ƙwayar cuta, kyakkyawar juriya na kyallen takarda na al'ada, tsawon rayuwa da kuma marasa lafiya masu dacewa. Ciwon daji na huhu na farko ya zama mai cin gajiyar wannan fasaha. SBRT wani tasiri ne mai ƙarancin sashi mara lahani wanda za'a iya yi a asibitin waje. Yawancin lokaci ana yin magani sau 1-5, sau ɗaya a rana ko kowace rana.

Tsarin tiyata na rediyo na EDGE wanda Asibitin Henry Ford ke amfani da shi a Amurka ƙarni ne na SBRT. Shi ne mafi yankan-baki mara cin zali tumo share fasaha zuwa yau. Zai iya rage lokacin jiyya na radiotherapy don kwayar cutar huhu zuwa minti 10-15, kuma an kammala dukan magani a cikin kwanaki 5. . Yawancin marasa lafiya na iya komawa rayuwa ta al'ada nan da nan bayan jiyya.

SBRT na ciwon huhu wanda ba za a iya cirewa ta hanyar tiyata ba

RTOG 0236 shine binciken asibiti na farko na tsakiya a Arewacin Amurka don kula da SBRT don rashin aiki na asibiti da wuri. kwayar cutar huhu. Nazarin asibiti na RTOG 0236 ya fara a cikin 2004 kuma ya kula da marasa lafiya 57 gabaɗaya. A cikin 2006, an shigar da marasa lafiya. Sakamakon asibiti yana da kyau sosai: ƙimar kula da ƙwayar cuta ta farko ta shekaru 3 ya kai 98%, kuma adadin tsira shine 56%.

Aiwatar da SBRT zuwa cutar kansar huhu da aka yi wa tiyata

Sakamakon jiyya na SBRT don ciwon huhu mara aiki ya nuna cewa yana iya kawar da ƙwayar cuta ta farko yadda ya kamata, kuma haƙuri kuma ya fi kyau a cikin wannan ɓangaren yawan masu haɗari. Bisa la'akari da haka, yiwuwar yin amfani da shi a cikin marasa lafiya da ciwon huhu mai aiki ya sami kulawa. Sakamakon asibiti ya nuna cewa muddin aka ba da madaidaicin adadin radiation, jiyya na SBRT na iya samun sakamako na warkewa wanda ke kusa da na tiyata ko ma lobectomy.

Wuka ta gaba mai sauri ita ce fasahar jiyya ta SBRT mafi ci gaba har zuwa yau

Tsarin EDGE ba tare da ɓarna ba tsarin jiyya na rediyo shine tsarin maganin kansar da FDA ta Amurka ta amince da shi a cikin 2014. Ya kasance mafi inganci tsarin tiyata na rediyo. Yana da wahala a yi aikin tiyata na yau da kullun akan ciwace-ciwacen daji kamar ciwace-ciwacen kai, ciwon huhu, da ciwan kashin baya. , Ciwon daji da sauran ciwace-ciwacen ciwace-ciwace suna da tasirin jiyya waɗanda ke da wahala a cimma su tare da aikin tiyata na al'ada da kayan aikin rediyo, kuma sune mafi kyawun zaɓi ga masu cutar kansa don cire cututtukan tumo zuwa yanzu.

Tun daga Afrilu 2014, tsarin farko na ciwon EDGE na duniya wanda ba zai iya cutar da shi ba yana aiki a cikin dukkan tsarin asibitin Henry Ford da ke Amurka. Ya yi jinyar marasa lafiya fiye da 400, kuma ƙimar gamsuwar jiyya (Tumor Co ntrol Rate) ya fi 95%. Kuma babu wani mummunan halayen da ya faru. Daga cikin wa] annan majinyatan ciwon, ciwace-ciwacen kwakwalwa (ciki har da ciwace-ciwacen da ke cikin kwakwalwa na farko da na metastatic) sun kai kashi 31%, ciwon huhu ya kai kashi 29%, ciwace-ciwacen kashin baya ya kai kashi 23%. ciwan ciki ya kai kashi 9%, kuma ciwon daji na adrenal ya kai kashi 7%.

Biyan kuɗi zuwa ga Newsletter

Sami sabuntawa kuma kada ku rasa bulogi daga Cancerfax

Toarin Don Bincika

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS
Cancer

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS

Lutetium Lu 177 dotatate, magani mai ban sha'awa, kwanan nan ya sami izini daga Hukumar Abinci da Magunguna ta Amurka (FDA) ga marasa lafiya na yara, wanda ke nuna gagarumin ci gaba a cikin ilimin cututtukan cututtukan yara. Wannan amincewar tana wakiltar alamar bege ga yara masu fama da ciwace-ciwacen ƙwayoyin cuta na neuroendocrine (NETs), nau'in ciwon daji da ba kasafai ba amma ƙalubale wanda galibi ke tabbatar da juriya ga hanyoyin warkewa na al'ada.

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.
Ciwon daji na bladder

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.

“Nogapendekin Alfa Inbakicept-PMLN, wani labari na rigakafi, yana nuna alƙawarin magance cutar kansar mafitsara idan aka haɗa shi da maganin BCG. Wannan sabuwar dabarar ta shafi takamaiman alamomin cutar kansa yayin da ake ba da amsa ga tsarin rigakafi, yana haɓaka ingancin jiyya na gargajiya kamar BCG. Gwajin gwaje-gwaje na asibiti suna bayyana sakamako masu ƙarfafawa, yana nuna ingantattun sakamakon haƙuri da yuwuwar ci gaba a cikin sarrafa kansar mafitsara. Haɗin kai tsakanin Nogapendekin Alfa Inbakicept-PMLN da BCG yana sanar da sabon zamani a cikin maganin cutar kansar mafitsara."

Ana buƙatar taimako? Ourungiyarmu a shirye take don taimaka muku.

Muna fatan samun lafiya cikin sauri na masoyinku da na kusa.

Fara hira
Muna Kan layi! Yi Taɗi da Mu!
Duba lambar
Hello,

Barka da zuwa CancerFax!

CancerFax wani dandali ne na majagaba wanda aka keɓe don haɗa mutane da ke fuskantar ciwon daji na zamani tare da hanyoyin kwantar da hankali kamar CAR T-Cell far, TIL far, da gwaji na asibiti a duk duniya.

Bari mu san abin da za mu iya yi muku.

1) Maganin ciwon daji a kasashen waje?
2) CAR T-Cell far
3) rigakafin cutar daji
4) Shawarar bidiyo ta kan layi
5) Maganin Proton